In this report
we feature a commentary by Alex M. Brill, CEO of Matrix Global Advisors and
a research fellow at the American Enterprise Institute, who testifi ed before the U.S.
House Judiciary Committee’s Subcommittee on Courts and Competition on July 14,
2009, regarding data exclusivity for biosimilars. We also provide insights from an
interviewed health policy lobbyist who is active in government affairs in Washington,
D.C. He spoke on background concerning recent negotiations on healthcare reform,
authorized generics, and reverse payment deals. Kevin E. Noonan, J.D., Ph.D., a
partner at McDonnell Boehnen Hulbert & Berghoff, gives his insights on patent reform
and healthcare reform.
(0 items)
